期刊文献+

铼[^(188)Re]羰基化合物标记含RGD的环肽及其生物分布 被引量:3

Radiolabeling and biodistribution of RGD peptide with ^(188)Re-tricarbonyl complex
下载PDF
导出
摘要 以fac-[188Re(CO)3(H2O)3]+为前体标记了含RGD的环形多肽,并对其在普通小鼠和荷S180肉瘤小鼠体内的生物分布作了初步研究。铼[188Re]羰基化合物标记含RGD环肽标记方法简单易行,75℃反应30min,标记率在90%以上。不会引起红细胞的溶血和凝聚现象,普通小鼠和荷S180肉瘤小鼠的生物分布实验表明,标记肽主要通过泌尿系统和肝胆代谢两个途径清除,1、4、24和48h肿瘤/肌肉比分别为:(4.4075±0.1139)、(5.1510±0.5375)、(4.4727±0.4895)和(4.8788±3.16)。 Three amino acids residues of Arg-Gly-Asp (RGD) are often the primary site of recognition by integrins which are responsible for tumor invasion and metastasis. In this research, one peptides containing RGD: HCRGD(D) FC were radiolabeled with ^188Re-wicarbonyl complex. High radiolabeling ratios (〉90%) were achieved under the reaction condition of 75℃, 30min. The radiolabeled peptide got high stability in PBS at room temperature for 4 hours. The hemolysis of red blood cells was not observed during incubation at 37℃ for 3 hours. Biodistribution studies were performed in normal male mice and S180-bearing mice, respectively. The radioactivities were rapidly eliminated by the hepatobiliary and urinary systems. Tumor/Muscle ratios were 4.4075±0. 1139, 5.1510±0.5375, 4.4727±0.4895 and 4.8788±3.16 at 1h, 4h, 24h and 48h after injection. The results showed that ^188Re-tricarbonyl peptide containing RGD was a potential agent for tumor treatment.
出处 《核技术》 EI CAS CSCD 北大核心 2006年第6期448-452,共5页 Nuclear Techniques
基金 中国科学院知识创新工程重大项目(KJCXI-SW-08) 国家自然科学基金项目(20501022) 国家自然科学基金项目(10405034)
关键词 铼-188羰基化合物 含RGD的多肽 生物分布 ^188Re-tricarbonyl complex, RGD-containing peptides, Biodiswibution
  • 相关文献

参考文献12

二级参考文献43

  • 1[2]Wolfsberg TG. White JM. ADAMs in fertilization and development[J] . Dev Biol, 1996, 180:389-401.
  • 2[3]Scarborough RM, Rose JW, Hsu MA, et al. Barbourin: A GpⅡb-Iia-specific integrin antagonist from the venom of Sistrurusm. Barbouri[J]. J Biol Chem, 1991, 266:9359-9362.
  • 3[4]Niewiarowski S, Mclane MA, Kloczewiak M. et al. Disintegrins and other naturally occurring antagoniss of platelet fibrinogen receptors[J]. Semin Hematol, 1994, 31:289-300.
  • 4[5]Jones JI, Prevette T, Gockerman A, et al. Ligand occupancy of the alphavbeta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor[J]. Proc Natl Acad Sci USA, 1996, 93:2482-2487.
  • 5[6]McLane MA, Kowalska MA, Silver Lshattil SJ, et al. Interaction of disintegrins with the apphaⅡbbeta3 receptor on resting and activated human platelets[J]. Biochem J, 1994, 301:429-436.
  • 6[7]Brunger AT, Krukowski A, Erickson JW. Slow-cooling protocols fox crystallographic refinement by simulated annealing[J]. Acta Crystallogr A, 1990, 46:585-593.
  • 7[8]McLane MA, Marcinkiewicz C, Wierzbicka I, et al. Effect of a double mutation in the RGD loop of the disintegrin echistatin on its interaction with αⅡbβ3 andαvbβ3integrins[J].Blood,1996, 88:59.
  • 8[9]Scarborough R, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms[J]. J Biol Chem,1993, 268:1058-1065.
  • 9[10]Beviglia L, Stewart GJ, Niewiarowski S. Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model[J]. Oncol Res,1995, 7:7-20.
  • 10[11]Scaloni A, Di Martino E, Miraglia N, et al. Amino acid sequence and molecular moedlling of glycoprotein Ⅱb-Ⅱa and fibronectin receptor iso-antagonists from Trimeresurus elegans venom[J]. Biochem J, 1996, 319:775-782.

共引文献12

同被引文献44

  • 1Nicosia R F, Bonanno E. Inhibition of Angiogenesis in Witro by RGD-Containing Synthetic Peptide [J]. Am J Pathol, 1991, 138: 829-833.
  • 2De S, Razorenova O, MeCabe N P, et al. VEGF- Integrin Interplay Controls Tumor Growth and Vascularization[J]. Proc Natl Acad Sci U S A, 2005, 102: 7 589-7 594.
  • 3Robinson S D, Reynolds L E, Wyder L, et al. β3- Integrin Regulates Vascular Endothelial Growth Factor-A-Dependent Permeability [J]. Arterioscler Thromb Vasc Biol, 2004, 24:2 108-2 114.
  • 4Friedlander M, Brooks P C, Shaffer R W, et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins[J]. Science, 1995, 270:1 500-1 502.
  • 5Kim J W, Lee H S. Tumor Targeting by Doxorubicin-RGD-4C Peptide Conjugate in an Orthotopic Mouse Hepatoma Model [J]. Int J Mol Med, 2004, 14: 529-535.
  • 6Chen X Y, Liu S, Hou Y P, et al. MicroPET Imaging of Breast Cancer αv-Integrin Expression With ^84Cu-Labeled Dimeric RGD Peptides [J]. Mol Imag Biol, 2004, 6(5): 356-359.
  • 7Chen X Y, Park R, Shahinian A H, et al. Pharmacokinetics and Tumor Retention of ^125I-Labeled RGD Peptide are Improved by PEGylation [J]. Nucl Med Biol, 2004, 31:11-19.
  • 8Haubner R, Brucheritseifer M, Bock M, et al. Synthesis and Biological Evaluation of a ^99Tc^m-Labelied Cyclic RGD Peptide for Imaging αvβ3 Expression[J]. Nuklearmedizin, 2004, 43: 26-32.
  • 9Psimadas D, Fani M, Zikos C, et al. Study of the Labeling of Two Novel RGD-Peptidic Derivatives With the Precursor [^99Tc^m (H2O)3 (CO)3]^+ and Evaluation for Early Angiogenesis Detection in Cancer[J].Appl Radiat Isot, 2004, 31: 11-19.
  • 10Dijkgraaf I, Kruijtzer J A W, Frielink C, et al. αvβ3 Integrin-Targeting of Intraperitoneally Growing Tumours With a Radiolabeled RGD Peptide [J]. Int J Cancer, 2006, 120: 605-610.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部